Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.59% | -26.76% | -3.64% | -19.06% | -33.84% |
| Total Depreciation and Amortization | 12.07% | -1.38% | -3.84% | -6.12% | -7.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.42% | 49.86% | 50.74% | -17.78% | 111.30% |
| Change in Net Operating Assets | 182.96% | 473.66% | -149.36% | 54.38% | 79.05% |
| Cash from Operations | -25.73% | 0.38% | -25.34% | -22.46% | 4.05% |
| Capital Expenditure | 63.97% | -10.34% | 23.95% | 67.83% | -1,100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 205.10% | 129.01% | 176.80% | 132.82% | -247.55% |
| Cash from Investing | 202.65% | 128.85% | 175.92% | 131.55% | -250.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 60.00% | -46.15% | -8.33% | 12.50% | -36.36% |
| Issuance of Common Stock | 957.89% | -89.08% | 6,815.38% | -83.61% | -96.98% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4,775.00% | -89.13% | 7,312.21% | -86.47% | 100.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.87% | -53.05% | 127.46% | 69.42% | -3,837.37% |